Shearman & Sterling advised Caris Life Sciences, Inc. as borrower on a $400 million senior secured term loan facility provided by OrbiMed and Braidwell. Proceeds of the financing will be used to repay a portion of Caris’s outstanding debt, enhance the company’s precision medicine platform and for general corporate purposes.

Headquartered in Irving, Texas, Caris is a leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Shearman advised Caris on its $235 million Series C equity financing and $75 million in debt financing in 2020, and on its $830 million Series D growth equity round in 2021.

The Team